There are currently 618 clinical trials in Austin, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, Dell Childrens Medical Center of Central Texas, Pfizer Investigational Site and University of Texas at Austin. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
NCT02493478
Recruiting
Advanced airway interventions are common high risk, high stakes events for children in intensive care units (ICU) and emergency departments (ED), with risk for life and health threatening consequences.
Gender:
ALL
Ages:
All
Trial Updated:
01/21/2025
Locations: Dell Children's Medical Center - Ascension, Austin, Texas
Conditions: Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Register for Updates
Anesthetics and Analgesics in Children
NCT03427736
Recruiting
The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
01/21/2025
Locations: Dell Children's Medical Center of Texas, Austin, Texas
Conditions: Anesthesia, Pain
Register for Updates
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
NCT06413433
Recruiting
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Austin, Texas +1 locations
Conditions: Binge-Eating Disorder
Register for Updates
Mitigating PTSD-CUD After Sexual Assault
NCT05989841
Recruiting
683,000 women are sexually assaulted annually in the United States, half of whom develop chronic posttraumatic stress disorder (PTSD) and thus have markedly increased risk for cannabis use disorder (CUD). The current proposal will test the acceptability, initial efficacy, and mechanisms underlying a novel digital therapeutic targeting risk for PTSD-CUD, which could address the critical need for PTSD-CUD prevention for the 100,000 women who annually present for emergency care after sexual assault... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: SAFE Austin, Austin, Texas
Conditions: Posttraumatic Stress Disorder, Cannabis Use Disorder
Register for Updates
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
Recruiting
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: USON - Texas Oncology, Austin Central, Austin, Texas
Conditions: Endometrial Cancer
Register for Updates
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
NCT06457685
Recruiting
POWER PAD 2 is a prospective, single-arm, multicenter, non-randomized clinical study designed to demonstrate the safety and effectiveness of the Amplitude Vascular Systems (AVS) Pulse Intravascular Lithotripsy™ (Pulse IVL™) System for treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Ascension Seton, Austin, Texas
Conditions: Peripheral Arterial Disease (PAD)
Register for Updates
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604
Recruiting
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Research Site, Austin, Texas
Conditions: HER2 Positive Metastatic Breast Cancer
Register for Updates
Sensor-controlled Digital Game for Heart Failure Self-management: A Clinical Trial
NCT05056129
Recruiting
This study evaluates a sensor-controlled digital game (SCDG) to motivate self-management behaviors of weight monitoring and physical activity in adults with heart failure (HF). Half of the participants will receive the SCDG app and weight monitoring and physical activity sensors and the other half will receive only the weight monitoring and physical activity sensors.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
01/16/2025
Locations: The University of Texas Austin, Austin, Texas
Conditions: Heart Failure
Register for Updates
A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors
NCT04892017
Recruiting
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: NEXT Oncology, Austin, Texas
Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067
Recruiting
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2025
Locations: Texas Oncology- Austin Midtown, Austin, Texas
Conditions: Advanced or Metastatic NRAS-mutant Melanoma
Register for Updates
A Study of STAR-0310 in Healthy Adult Participants
NCT06782477
Recruiting
This is a randomized, double-blind, placebo-controlled, single ascending dose trial evaluating the safety, tolerability, PK, and immunogenicity of STAR-0310 in healthy adult participants. There are 4 planned cohorts and potentially up to 1 additional cohort which may comprise of healthy adult participants of Japanese descent.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/15/2025
Locations: Austin Clinical Research Unit - Early Clinical Development, Austin, Texas
Conditions: Healthy Participants
Register for Updates
HEAL-IST IDE Trial
NCT05280093
Recruiting
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/13/2025
Locations: Texas Cardiac Arrhythmia Research Foundation, Austin, Texas
Conditions: Inappropriate Sinus Tachycardia
Register for Updates